BRIEF published on 02/22/2024 at 17:45, 1 year 9 months ago Armacell presents its financial results for the year 2023 EBITDA CEO Transition Growth Armacell Financial Results 2023
PRESS RELEASE published on 02/22/2024 at 17:45, 1 year 9 months ago Armacell Financial Highlights 2023 Armacell reports 3.7% increase in net sales to EUR 836.1 million in 2023 along with adjusted EBITDA of EUR 154.6 million. CEO transition in progress Adjusted EBITDA CEO Transition Net Sales Financial Highlights Armacell
PRESS RELEASE published on 02/13/2024 at 15:00, 1 year 9 months ago Armacell Announces Transition of CEO Armacell announces transition of CEO, with Patrick Mathieu becoming Non-Executive Director and Laurent Musy appointed as new CEO. Focus on sustainable growth and energy savings CEO Transition Sustainable Growth Energy Savings Armacell New Appointment
PRESS RELEASE published on 06/19/2023 at 12:24, 2 years 5 months ago Armacell : Armacell and AIS establish joint venture for insulation jackets
PRESS RELEASE published on 02/23/2023 at 16:47, 2 years 9 months ago Armacell Financial Highlights 2022
Published on 12/05/2025 at 02:35, 4 hours 33 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 8 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 3 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 8 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 3 hours 37 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 17 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 42 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 53 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 57 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 13 hours 8 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 23 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 13 hours 23 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 13 hours ago Declaration of voting rights at the end of November 2025
